Nuvalent (NASDAQ:NUVL) Insider Sells $1,575,288.00 in Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Deborah Ann Miller sold 14,300 shares of the company’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $110.16, for a total transaction of $1,575,288.00. Following the completion of the sale, the insider directly owned 59,634 shares in the company, valued at approximately $6,569,281.44. The trade was a 19.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Deborah Ann Miller also recently made the following trade(s):

• On Wednesday, January 21st, Deborah Ann Miller sold 700 shares of Nuvalent stock. The shares were sold at an average price of $109.84, for a total value of $76,888.00.
• On Tuesday, January 6th, Deborah Ann Miller sold 2,589 shares of Nuvalent stock. The stock was sold at an average price of $97.16, for a total value of $251,547.24.
• On Monday, January 5th, Deborah Ann Miller sold 4,363 shares of Nuvalent stock. The stock was sold at an average price of $97.32, for a total value of $424,607.16.
• On Monday, November 17th, Deborah Ann Miller sold 24,200 shares of Nuvalent stock. The shares were sold at an average price of $105.50, for a total value of $2,553,100.00.
• On Thursday, October 30th, Deborah Ann Miller sold 21,800 shares of Nuvalent stock. The stock was sold at an average price of $103.16, for a total value of $2,248,888.00.

Nuvalent Price Performance

Shares of NASDAQ NUVL opened at $106.44 on Monday. The stock has a market capitalization of $7.74 billion, a price-to-earnings ratio of -20.01 and a beta of 1.32. The firm’s 50 day simple moving average is $105.12 and its 200-day simple moving average is $91.22. Nuvalent, Inc. has a 12 month low of $55.53 and a 12 month high of $113.01.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same quarter in the previous year, the business posted ($1.28) EPS. Analysts anticipate that Nuvalent, Inc. will post -3.86 earnings per share for the current fiscal year.

Institutional Trading of Nuvalent

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after purchasing an additional 108 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Nuvalent in the third quarter valued at about $38,000. Eastern Bank purchased a new position in shares of Nuvalent in the third quarter worth about $52,000. Persistent Asset Partners Ltd acquired a new position in Nuvalent during the second quarter worth about $88,000. Finally, Farther Finance Advisors LLC boosted its position in Nuvalent by 9,230.8% during the second quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock worth $93,000 after acquiring an additional 1,200 shares during the last quarter. 97.26% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NUVL. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvalent in a research note on Thursday. Wedbush reissued an “outperform” rating and issued a $125.00 price objective (up from $120.00) on shares of Nuvalent in a report on Monday, November 17th. UBS Group reaffirmed a “buy” rating on shares of Nuvalent in a research note on Wednesday, December 17th. Stifel Nicolaus lifted their price target on shares of Nuvalent from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Finally, Truist Financial set a $140.00 price target on shares of Nuvalent in a report on Monday, November 24th. Fifteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Nuvalent currently has an average rating of “Moderate Buy” and a consensus price target of $138.33.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.